louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04978025: Colloidal Silver, Treatment of COVID-19
Official title: The Value of Colloidal Silver in the Treatment of COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: SARS (Severe Acute Respiratory Syndrome)
Keywords: colloidal silver
treatment
COVID-19
Lead sponsor: Hôpital Universitaire Sahloul
Sponsor class: OTHER
First posted: 2021-07-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I

Detailed description: Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy.

The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

Eligibility criteria: Inclusion Criteria:

* Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.

Exclusion Criteria:

* Any pregnant or breastfeeding woman
* patient with an expectation of survival of less than 24 hours
* Dyspnea leading to heart failure
* Hepatic insufficiency
* Chronic respiratory failure
* Renal failure, clearance \<20ml • min-1 • 1.73 • m-²

Primary outcomes:
measure: Chage of clinical status
timeFrame: 10 DAYS
Secondary outcomes:
measure: Adverse events
timeFrame: ON 1 month
measure: the duration of hospitalization
timeFrame: ON 11 days
measure: the duration of the different respiratory assistance modes
timeFrame: ON 11 days
measure: all-cause mortality
timeFrame: ON 1 month
Other outcomes:
Locations:
city: Sousse
country: Tunisia
facility: HU Sahloul, sousse, Tunisia
state: Itinéraire Ceinture Cité Sahloul
Study officials:
affiliation: HU Sahloul
name: Boukef Riadh, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05856825: Long-Term Outcomes of Robot-Assisted Radical Cystectomy: A Real-World Study
Official title: Long-Term Outcomes of Robot-Assisted Radical Cystectomy: A Real-World Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bladder Cancer
Robot-assisted Radical Cystectomy
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2023-05-12
Enrollment: 4500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who underwent robot-assisted radical cystectomy for bladder cancer from 2012 to 2021 in 32 large medical institutions in China.

Brief summary: A multicenter, retrospective research was conducted. Patients who underwent robot-assisted radical cystectomy (RARC) from for bladder cancer in 32 institutions in China were enrolled in this study. Baseline condition, perioperative, pathological, and survival outcome were collected. The study was aimed to report the real-world condition of RARC in China, and evaluate its effectiveness.


Eligibility criteria: Inclusion Criteria:

* \>18 years old; Clinical stage Ta-T4a/N0-3/M0.

Exclusion Criteria:

* Severe cardiovascular disease; history of previous major abdominopelvic surgery; patients with distant metastases; medical history of malignancy in other organs.

Primary outcomes:
measure: Overall survival
timeFrame: Five years
measure: Recurrence-free survival
timeFrame: Five years
measure: Cancer-specific survival
timeFrame: Five years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05682625: Understanding COVID-19 Vaccine Immunity in Tissue and Blood
Official title: Understanding COVID-19 Vaccine Immunity in Tissue and Blood
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: COVID-19 (Coronavirus Disease 2019)
Keywords: Immunity
Vaccine
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2023-01-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults (18 years and older) receiving a COVID-19 vaccine

Brief summary: The purpose of this study is to understand the effects of COVID-19 vaccines on the immune system and how the COVID-19 vaccines provide protection and induce long term memory. Adults who are receiving a COVID-19 vaccine will be invited to participate in this study.


Eligibility criteria: Inclusion Criteria:

* Adults 18yrs old and higher who are receiving a COVID-19 vaccine

Exclusion Criteria:

* Pregnancy
* Patients with contraindications for lymph node biopsy
* Active cancer
* Current use of immunosuppression drugs

Primary outcomes:
measure: Testing immune response to the COVID-19 vaccine over time
timeFrame: 1 day
measure: Testing immune response to the COVID-19 vaccine over time
timeFrame: 7 days
measure: Testing immune response to the COVID-19 vaccine over time
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University, Sean N. Parker Center for Allergy and Asthma Research
name: R. Sharon Chinthrajah, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03668925: Association Between Hidradenitis Suppurativa and Spondyloarthritis
Official title: Association Between Hidradenitis Suppurativa and Spondyloarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hidradenitis Suppurativa
Keywords: spondyloarthritis
hidrosadenitis suppurativa
inflammation
magnetic resonance imaging
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2018-09-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Hidradenitis suppurativa is a chronic dermatosis, characterized by an inflammation of the follicular epithelium in the apocrine glands.

The hypothesis of a link between hidradenitis suppurativa and inflammatory rheumatism has been widely considered, with evidence in support of this theory accumulating from several case reports and small series. The most frequently cited rheumatismal disease thought to be associated with Hidradenitis suppurativa is spondyloarthritis.

Taken together, these data suggest that there may a link between hidradenitis suppurativa and spondyloarthritis, but literature data are sparse, and to date, no study has investigated or demonstrated such a relation. Indeed, existing studies to date were observational, descriptive, and retrospective, and did not use modern diagnostic approaches for documenting spondyloarthritis, such as magnetic resonance imaging (MRI) or the recent classification of spondyloarthritis.

Detailed description: The aim of the study was to test the hypothesis that the risk of spondyloarthritis is increased in patients with hidradenitis suppurativa.

Eligibility criteria: Inclusion Criteria:

* for case: patients with diagnosis of hidrosadenitis suppurativa in the Department of Dermatology of the University Hospital of Reims, regardless of the stage of severity and duration of their disease
* for control: patients without diagnosis of hidrosadenitis suppurativa matched to cases for age (±5 years) and sex
* for case and control: have accepted to take part in the research

Exclusion Criteria:

* for case and control: age \<18 years old

Primary outcomes:
measure: spondyloarthritis
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Damien JOLLY
Study officials:
References:
citation: Fauconier M, Reguiai Z, Barbe C, Colosio A, Eschard JP, Salmon JH, Direz G. Association between hidradenitis suppurativa and spondyloarthritis. Joint Bone Spine. 2018 Oct;85(5):593-597. doi: 10.1016/j.jbspin.2017.09.005. Epub 2017 Sep 28.
Clinical trial NCT06757725: Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
Official title: Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Systemic Lupus Erthematosus
Lupus Glomerulonephritis
Lupus Flare
Keywords: systimc lupus erythromatosus
lupus glomerulonephritis
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2025-01-03
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis

Detailed description: we have recruited patients into 3 groups The first group is patients with lupus nephritis The second groups is patients with systemic lupus erythromatosus without nephritis The third groups is normal healthy controls we explored the association of colour Doppler and the renal resistive index with the degree of the renal affection in lupus nephritis

Eligibility criteria: Inclusion Criteria:

* 1. Systemic lupus erythematosus. 2. Lupus nephritis. 3. Adults \>18 years old.

Exclusion Criteria:

* 1. End Stage Renal Disease. 2. Diabetes Mellitus. 3. Heart failure. 4. Hepatic diseases. 5. Obstructive nephropathy. 6. Renal artery stenosis or occlusion.

Primary outcomes:
measure: Resistive index
timeFrame: At the time of recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University Hospitals
Study officials:
References:
Clinical trial NCT00260325: Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers
Official title: Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia: a Randomized Controlled Trial in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Hyperalgesia
Keywords: pretreatment
healthy volunteers
Lead sponsor: Penn State University
Sponsor class: OTHER
Collaborators: name: Pfizer
name: National Institutes of Health (NIH)
First posted: 2005-12-01
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Tis study was designed to test the hypothesis that pretreatment with valdecoxib, prior to injury could reduce or prevent the development of secondary hyperalgesia around the area of primary injury. A heat/capsaicin model of induced hyperalgesia was tested in healthy volunteers in a randomized, double blind, cross-over trial of a single dose of 40 mg vadecoxib versus control. Subjects rated pain intesnsity and unpleasantness following heat stimulation of the forearm, the area of hyperalgesia was also mapped over the course of the experiment.


Eligibility criteria: Inclusion Criteria:

* healthy male of non-pregnant female; 18yo or older
* not currently taking NSAID
* able and willing to provide informed consent
* willing to avoid other NSAIDs in 24 hour period following study
* no known hypersentitivites or contraindications to NSAIDS, sulfonomides or capsaicin

Exclusion Criteria:

* pregnant or breast feeding
* use of NSAIDS or other analgesic medications in past 7 days
* unwilling or unable to give informed consent
* contraindication to any study medication or other NSAID

Primary outcomes:
measure: Reduction in the area of secondary hyperalgesia
Secondary outcomes:
measure: Reduction in pain threshold
measure: Reduction in pain unpleasantness
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State University College of Medicine
state: Pennsylvania
Study officials:
affiliation: Penn State University, Dept of Anesthesiology
name: Piotr K Janicki, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00203125: A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
Official title: Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Parkinson's Disease
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2005-09-20
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo


Eligibility criteria: Inclusion Criteria:

Men and women with idiopathic Parkinson's disease (PD) who have met inclusion criteria for PRESTO, and have completed the 26-week PRESTO study. The subject should be available to participate in the sub-study immediately following the last PRESTO visit (same day). Subjects must continue PRESTO study drug until the morning of the Tyramine Sub-Study.

Subjects must provide separate informed consent to participate in the Tyramine Sub-Study.

Exclusion Criteria:

Subjects must not have a history of intracranial aneurysm or stroke.

Subjects should not have uncontrolled hypertension, defined as systolic pressure \> 160 mmHg, or diastolic pressure \> 90 mmHg.

Primary outcomes:
measure: An increase in systolic blood pressure of > 30mmHg from the mean baseline value (documented by at least 3 consecutive measurements). Or Bradycardia with a heart rate below 40 beats per minute
timeFrame: 26 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Teva Neuroscience, Inc.
name: Phyllis Salzman, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00249925: Project ABLE:Advancing Better Living for Elders
Official title: Enhancing Function of Frail Elders At Home
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Frail Elderly
Keywords: Home modification
Occupational Therapy
Physical Therapy
Home care
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2005-11-07
Enrollment: 319
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The specific aims of the study are to: 1) test the effectiveness of a home-bases intervention to improve home safety, fall efficacy and functional performance; 2) determine if the use of environmental strategies results in occurrence of less negative health events (falls and depression); 3) compare types of environmental strategies accepted and used under different treatment conditions; and 4) evaluate the cost-effectiveness of the intervention program.


Eligibility criteria: Inclusion Criteria:

* 70 years or older
* community dwelling
* functional vulnerability/HRCA vulnerability index= \>1 problem area

Exclusion Criteria:

* Mini-Mental Status Examination (MMSE) score of less than or equal to 23
* legal blindness
* bed bound
* nursing home placement or relocation expected within 12 months of study eligibility

Primary outcomes:
measure: Functional difficulty
measure: Fear of falling
measure: Self-efficacy
Secondary outcomes:
measure: Home hazards
measure: Control oriented strategy use
measure: Mortality
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Philadelphia Corporation for Aging (PCA)
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Laura N Gitlin, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rose KC, Gitlin LN, Dennis MP. Readiness to use compensatory strategies among older adults with functional difficulties. Int Psychogeriatr. 2010 Dec;22(8):1225-39. doi: 10.1017/S1041610210001584. Epub 2010 Jul 27.
Clinical trial NCT03029325: Molecular and Genetic Analysis of Lung Cancer
Official title: Molecular and Genetic Analysis of Lung Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2017-01-24
Enrollment: 15000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lung cancer cases and healthy controls are recruited from Massachusetts General Hospital patient population. Cases come from Thoracic Surgery or Cancer Center. Controls are usually spouses or friends of cases, or in some cases unrelated to a specific case.

Brief summary: Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Detailed description: Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.

Eligibility criteria: Inclusion Criteria:

* healthy controls: participants without evidence of any cancer
* cases: pathology proven primary lung cancer

Exclusion Criteria:

* younger than 18 years old

Primary outcomes:
measure: Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
timeFrame: 20 years
Secondary outcomes:
measure: Overall survival
timeFrame: 20 years
measure: Progression-free survival
timeFrame: 20 years
measure: Treatment toxicities
timeFrame: 20 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Harvard TH Chan School of Public Health
name: David C Christiani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01854125: Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites
Official title: Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Immune Function in Blood
Liver Function in Blood
Variation of Ascites
Characters of Quality of Life
Child-Pugh Score
Keywords: immun function
liver function
ascites
quality of life
Child-Pugh score
Lead sponsor: Nanjing PLA General Hospital
Sponsor class: OTHER
First posted: 2013-05-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in liver cirrhosis patients with refractory ascites are very wretched. The objective of this study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem cells (BMSCs) transplantation via liver artery in Child-Pugh B and C stage of liver cirrhosis patients with refractory ascites. The immunomodulatory impact of MSCs in fibrosis was confirmed, and several clinical studies have applied MSCs to eliminate the progression of fibrosis. In this research the investigators will study the affect and influence of MSCs in the patients,include assay of liver function,variation of ascites,Child-Pugh score etc.


Eligibility criteria: Inclusion Criteria:Inclusion Criteria:

Aged 18\~65 years. Ultrasonographic evidences of cirrhosis. hepatic cirrhosis patients with refractory ascite.

Exclusion Criteria:

history of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrolment.

Prothrombin time is less than 30s. Severe problems in other vital organs(e.g.the heart,renal or lungs). Liver tumor on ultrasonography, CT or MRI examination. Pregnant or lactating women. Imaging evidences of vascular thromboses.

-

Exclusion Criteria:

-

Primary outcomes:
measure: change in immune function,liver function in blood
timeFrame: before and one to 12 weeks after therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Jinling Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing University
name: Fangyu Wang, MD/PhD
role: STUDY_DIRECTOR
affiliation: Nanjin University
name: Fangyu Wang, MD/PhD
role: STUDY_DIRECTOR
References:
citation: Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205. doi: 10.1097/MEG.0b013e32832a1f6c.
Clinical trial NCT05579925: A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
Official title: A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Lead sponsor: Keymed Biosciences Co.Ltd
Sponsor class: INDUSTRY
First posted: 2022-10-14
Enrollment: 24
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.


Eligibility criteria: Inclusion Criteria:

* 12 years ≤ age ≤ 18 years
* With atopic dermatis
* Voluntarily sign the informed consent form

Exclusion Criteria:

* Weight \< 30 kg
* Major surgery planed during the study

Primary outcomes:
measure: Adverse events
timeFrame: at week 14
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Children's Hospital Capital Medical University
Study officials:
References: